Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

63 results
Display

Erlotinib-related Severe Hair Loss with Severe Exanthematous Drug Eruption: A Case Report

Kang JN, Kim DH, Park SH, Seol JE, Kim H

  • KMID: 2436653
  • Korean J Dermatol.
  • 2018 Feb;56(2):139-142.
Erlotinib inhibits the epidermal growth factor receptor and is used in patients with various cancers. However, it can affect the epidermis and hair because the receptor is expressed in normal...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Pneumatosis Cystoides Intestinalis after Erlotinib-containing Chemotherapy for Pancreatic Cancer

Kim GY, Kim MK, Lee DW, Han J, Kim HG

Pneumatosis cystoides intestinalis (PCI) is an uncommon condition that is characterized by the presence of gas within the bowel wall. We experienced a case of PCI after erlotinib-containing chemotherapy for...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Acneiform Eruption Induced by Erlotinib (Tarceva(R))

Kim YY, Kim SY

  • KMID: 2248785
  • Korean J Dermatol.
  • 2007 Nov;45(11):1183-1186.
Erlotinib (Tarceva(R)) is a new anticancer agent, acting as a reversible tyrosine kinase inhibitor of the epidermal growth factor receptor. It blocks signal transduction pathways implicated in the proliferation and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Recurrent Erlotinib-Induced Interstitial Lung Disease on Non-Small Cell Lung Cancer

Park SD, Kim A, Park JS, Shin CH, Nam HS, Kim L, Cho JW, Ryu JS, Kwak SM

  • KMID: 2319282
  • Tuberc Respir Dis.
  • 2009 Nov;67(5):445-448.
Erlotinib (Tarceva(R)) has been considered to be a new, promising oral chemotherapy agent for local advanced or metastatic non-small cell lung cancer (NSCLC). Erlotinib is regarded as relatively safe, but...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Successful Rechallenge with Gefitinib for an Initial Erlotinib-Responder with Advanced Lung Adenocarcinoma

Hong SC, Sim YS, Lee JH, Ryu YJ, Chang JH

  • KMID: 2319566
  • Tuberc Respir Dis.
  • 2011 Oct;71(4):286-290.
Although failure of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI) is generally believed to be associated with cross-resistance to other EGFR TKI, the benefit of administering erlotinib as...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Erlotinib HCL (Tarceva(R)) Induced Radiation Recall Dermatitis

Kim HM, Lee SH, Kim CY

  • KMID: 2247677
  • Korean J Dermatol.
  • 2010 Oct;48(10):872-875.
Erlotinib (Tarceva(R)) is a new anti-cancer agent that acts by inhibiting epidermal growth factor receptor (EGFR) signal transduction. It is currently used in the treatment of advanced stage non-small cell...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Ovarian Metastasis from Non-Small Cell Lung Cancer Responding to Erlotinib

Jung IJ, Lim ST, Choi YS, Jang TS, Oh SH, Lee JA, Cho DY

Ovarian cancer is generally primary cancer and less frequently originates from metastasis from non-gynecological cancer. Ovarian metastasis from lung cancer represents only 2~4% of all ovarian metastatic cancers. We report...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Sequential Responses of Adenocarcinoma of the Lung to Erlotinib after Gefitinib in Never Smoker Korean Woman

Kim HK, Ahn MI, Yoo J, Kim CH, Yang HJ, Shim BY

  • KMID: 2166040
  • Cancer Res Treat.
  • 2007 Mar;39(1):37-39.
A patient with adenocarcinoma of the lung was treated sequentially using two kinds of EGFR tyrosine kinase inhibitors, gefitinib and erlotinib. The patient was a 73-year-old female who received gefitinib...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Black Hairy Tongue Associated with Erlotinib Treatment in a Patient with Advanced Lung Cancer

Jeong JS, Lee JY, Kim MK, Yoon TY

  • KMID: 2383260
  • Ann Dermatol.
  • 2011 Nov;23(4):526-528.
Erlotinib is a tyrosine kinase inhibitor that acts on the epidermal growth factor receptor (EGFR). There have been many reports of the mucocutaneous side effects related to several EGFR inhibitors...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Acneiform Eruption and Paronychia Occurring after Use of Erlotinib (Tarceva(R))

Yeon JH, Min SU, Lee DH, Choi YS, Suh DH

  • KMID: 2248784
  • Korean J Dermatol.
  • 2007 Nov;45(11):1180-1182.
Erlotinib (Tarceva(R)) is a new anti-cancer agent which acts by inhibiting epidermal growth factor receptor (EGFR) signal transduction. It is currently used in the treatment of advanced stage non-small cell...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Cicatricial Alopecia Associated with Erlotinib

Yang BH, Bang CY, Byun JW, Han SH, Song HJ, In SG, Shin JH, Choi GS

Erlotinib is a small-molecule tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR). Erlotinib has been used primarily to treat non-small cell lung cancer. In addition to its...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Erlotinib-Related Spontaneous Pneumothorax in Patient with Primary Lung Cancer

Nam HS, Lee HJ, Kim MS, Park SW, Jeon SH, Cho JH, Kwak SM, Lee HL, Ryu JS

  • KMID: 2319457
  • Tuberc Respir Dis.
  • 2010 Dec;69(6):465-468.
Spontaneous pneumothorax (SPTx) associated with primary lung cancer is quite rare, but has been reported as the initial presentation or a complication of disease progression. Moreover, chemotherapy-related SPTx in primary...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Erlotinib (Tarceva(R)) Induced Hair Abnormalities

Choi CM, Lew BL, Sim WY

  • KMID: 2247599
  • Korean J Dermatol.
  • 2011 Apr;49(4):382-384.
Erlotinib is a low-molecular-weight quinazoline derivative that inhibits the activation of epidermal growth factor receptor (EGFR) tyrosine kinase through competitive binding of the adenosine triphosphate binding domain of the receptor....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib

Kim Y, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM

PURPOSE: We tried to evaluate whether there are any specific features in treatment outcomes of firstline afatinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC),...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of the therapeutic outcome between gefitinib and erlotinib in female patients with non-small-cell lung cancer

Moon DS, Jang TW, Oak CH, Jung MH, Kim DH, Choi IS

  • KMID: 2257329
  • Korean J Med.
  • 2009 Feb;76(2):179-185.
BACKGROUND/AIMS: Lung cancer is the leading cause of cancer death worldwide. There are significant gender differences in lung cancer: most females with lung cancer are non-smokers and they are diagnosed...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Elevated Prothrombin Time-International Normalized Ratio (PT-INR) Associated with Concurrent Use of Erlotinib and Warfarin

Kim SK, Park KS, Choi SH, Byun JH, Woo IS, Han CH, Kim HL

  • KMID: 2259300
  • Korean J Med.
  • 2011 Jun;80(6):729-733.
Erlotinib, an orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is indicated for EGFR mutation-positive patients with poor performance status. Erlotinib is also used as a second-line...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Superficial Punctate Keratoepitheliopathy Under Treatment with Erlotinib and Lapatinib

Oh EK, Jo DH, Kim MK, Wee WR

PURPOSE: To report the corneal superficial punctate keratoepitheliopathy in 2 patients taking the epidermal growth factor receptor (EGFR) inhibitors, erlotinib and lapatinib, respectively. CASE SUMMARY: Case 1, who received erlotinib, showed...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients

Choi Y, Keam B, Kim M, Yoon S, Kim D, Choi JG, Seo JY, Park I, Lee JL

PURPOSE: Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare genetic syndrome resulting from germline mutations in fumarate hydratase. The combination of bevacizumab plus erlotinib showed promising interim results...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure

Cho KM, Keam B, Kim TM, Lee SH, Kim DW, Heo DS

BACKGROUND/AIMS: The purpose of this study was to identify predictive factors for erlotinib treatment in non-small cell lung cancer (NSCLC) patients following gefitinib failure. METHODS: Forty-five patients with NSCLC who were...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Two Cases of Acneiform Eruption Caused by Epidermal Growth Factor Receptor Inhibitors

Choi KW, Lee CY, Lee YK, Kim HS, Kim KH, Kim YH

  • KMID: 2248163
  • Korean J Dermatol.
  • 2008 Jun;46(6):862-865.
Epidermal growth factor receptor (EGFR) inhibitors are associated with unique and dramatical dermatological side effects. The most commonly encountered adverse effect is a mild skin toxicity characterized by a sterile...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr